Celldex Therapeutics, Inc. — Director's Dealing 2017

Jun 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2017-06-15

Reporting Person: PENNER HARRY JR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-15	Common Stock, par value $0.001 per share	A	10000	—	Acquired	41916	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-15	Non-Qualified Stock Option (right to buy)	$2.32	A	15000	Acquired	2027-06-15	Common Stock (15000)	Direct

Footnotes

F1: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.

F2: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.

F3: Such option vests in three equal annual installments beginning June 15, 2018.